Search
STALEVO 150 MG / 37.5 MG / 200 MG, Comprimé pelliculé
Details
| --- | Description |
|---|---|
| Pack | Boite de 30 |
| Strength (Dosage) | 150 MG | 37.5 MG | 200 MG |
| Laboratory | NOVARTIS PHARMA MAROC |
| Ingredients | Lévodopa (150 mg) | Carbidopa (37.5 mg) | Entacapone (200 mg) |
| Therapeutic class | Lévodopa, inhibiteur de la décarboxylase et inhibiteur de la COMT |
| ATC code | N04BA03 |
| PPH | $23.30 |
| PPV | $35.20 |
| Refundable | Yes |
| Refund base | $35.20 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Not specified |
| Uses | Stalevo est destiné au traitement des patients adultes atteints de la maladie de Parkinson et présentant des symptômes de fluctuations motrices (appelés de fin de dose ou symptômes on-off) qui ne peuvent être stabilisées avec l'association lévodopa/inhibiteur de la dopa décarboxylase. |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications under one or more of the therapeutic classes above
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem